[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641375":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":21,"locations":10,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Imperial College London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Chronic lung disease",null,"Patients with chronic lung disease who are colonised with a high priority antimicrobial resistant pathogen",[13,16,18],{"name":14,"affiliation":5,"role":15},"Anand Shah","PRINCIPAL_INVESTIGATOR",{"name":17,"affiliation":5,"role":15},"Aran Singanayagam",{"name":19,"affiliation":20,"role":15},"Raju Misra","UKHSA",[22],{"name":14,"role":23,"phone":24,"phoneExt":10,"email":25},"CONTACT","0044 20 7352 8121","s.anand@imperial.ac.uk",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641375","an-observational-study-into-antimicrobial-resistance-in-patients-with-a-chronic-lung-disease-100641375",false,"NCT07646691","An Observational Study Into Antimicrobial Resistance in Patients With a Chronic Lung Disease","Prospective Study of Antimicrobial RESIstance in Chronic Lung DiseasE","PRESIDE","Inclusion Criteria:\n\n* Presence of an underlying chronic lung disease (e.g. Bronchiectasis, COPD) stratified by colonisation status:\n\n  * Pseudomonas sp (n=30)\n  * Klebsiella sp (n=20)\n  * Haemophilus sp (n=20)\n  * E-coli sp (n=20)\n  * Stenotrophomonas sp (n=20)\n  * Staphylococcus sp (n=20)\n  * Other chronic colonisation (n=20)\n  * Not colonised with any bacterial pathogen (n=20)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Pregnancy\n* Medical instability preventing ability to attend for regular study visits at baseline.","ALL","18 Years",{"count":39,"type":40},170,"ESTIMATED","OBSERVATIONAL","Antimicrobial resistance (AMR) refers to the ability of microorganisms like bacteria, viruses, fungi and parasites to resist the effects of antimicrobial drugs (such as antibiotics) which are widely used as treatment. AMR poses an escalating global health threat, contributing to difficult-to-treat infections associated with increased disease spread, disability and death, as well as a substantial economic burden.\n\nIn chronic lung diseases, such as bronchiectasis, Cystic fibrosis or chronic obstructive lung disease (COPD), there is a higher risk of AMR due to the exposure to frequent or prolonged courses of antibiotics to treat recurrent lung infections and exacerbations (flares of the disease), to reduce lung inflammation or to control chronic infection within the lung with suppression of colonising microbes.\n\nMost data on AMR in chronic lung diseases derive from analysing pre-existing routinely collected health data collected on a national basis which is often incomplete. Hence a prospective study is crucial to better understand and address AMR in chronic lung diseases. Prospective studies follow patients forward in time, collecting data on outcomes and allowing researcher to observe the natural history of AMR development, monitor trends and evaluate interventions.\n\nThis multicentre prospective study, as part of the European Respiratory Society (ERS) Clinical Research Collaboration on Antimicrobial Resistance in Lung Disease (CRC - AMR Lung), aims to investigate the patterns of AMR in chronic lung diseases through a fully anonymous registry alongside a prospective sub-cohort study tracking individuals with chronic lung disease and known colonisation with high-priority AMR pathogens (microorganisms). This study will enable analysis of prevalence and burden of AMR within chronic lung disease alongside understand the genetic drivers of resistance, the link between the microbial genotype and antimicrobial resistance and how transmission of resistance occurs in chronic lung disease.",[44],"Chronic Lung Diseases",[46,47],"antimicrobial resistance","chronic lung disease","NOT_YET_RECRUITING","2026-06-17",{"date":51,"type":52},"2026-06-22","ACTUAL",{"date":54,"type":40},"2026-07-01",{"date":56,"type":40},"2028-12-01",{"name":5,"class":6}]